Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study

BACKGROUND: The efficacy and safety of pazopanib in patients diagnosed with metastatic renal cell carcinoma (mRCC) have been demonstrated by a Chinese subgroup analysis of the COMPARZ (Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma) trial. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jianhui, Ye, Wen, Jiang, Wei, Li, Xiaofan, Liu, Rong, Lin, Bijuan, Xiang, Jingnan, Tian, Wei, Bai, Junjie, Zuo, Teng, Lin, Bingxin, Guo, Yinan, Zheng, Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039632/
https://www.ncbi.nlm.nih.gov/pubmed/33850766
http://dx.doi.org/10.21037/tau-21-111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039632/
https://www.ncbi.nlm.nih.gov/pubmed/33850766
http://dx.doi.org/10.21037/tau-21-111

Ejemplares similares